National Institute of Allergy and Infectious Diseases (NIAID)s

National Institute of Allergy and Infectious Diseases (NIAID)

174 Protocols (128 Active Accrual of new subjects, 46 Follow-up of previously enrolled subjects)


Active Accrual, Protocols Recruiting New Patients 
* 000384-I:
Analysis of the Immune Response to COVID-19 Vaccination and Outcomes in Individuals With and Without Immune Deficiencies and Dysregulations

* 000291-I:
Observational Digital Biomarker Discovery in Respiratory Virus Challenge Studies

* 000256-I:
Natural History of Systemic and Nasal Mucosal Immunity to Influenza and SARS-CoV-2 in Adults after Vaccination

* 000233-I:
An International Multicenter, Adaptive, Randomized Double-Blind, Placebo-Controlled Trial of the Safety, Tolerability and Efficacy of Anti-Coronavirus Hyperimmune Intravenous Immunoglobulin for the Treatment of Adult Hospitalized Patients at Onset of Cli

* 000186-I:
Part B- Phase I/II, Non-randomized, Multicenter, Open-label Study of G1XCGD (Lentiviral Vector Transduced CD34+ Cells) in Patients with X-Linked Chronic Granulomatous Disease

* 21-I-0005:
Phase 1 Study of the Safety and Immunogenicity of an Epstein-Barr Virus (EBV) gp350-Ferritin Nanoparticle Vaccine in Healthy Adults With or Without EBV Infection

* 20-I-0145:
VRC 323: A Phase I Open-Label Clinical Trial to Evaluate the Dose, Safety, Tolerability and Immunogenicity of an Influenza H10 Stabilized Stem Ferritin Vaccine, VRC-FLUNPF0103-00-VP, in Healthy Adults

* 20-I-0140:
A Double-Blind, Randomized, Placebo-Controlled, Phase 1, Single-Dose, Dose-Escalating Trial of Long-Acting Recombinant Human IL-7 (NT-I7) for COVID-19

* 20-I-0132:
A Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, 24-week Phase 3 Study with an Open-label Extension to Evaluate the Efficacy and Safety of Benralizumab in Patients with Hypereosinophilic Syndrome (HES)

* 20-I-0123:
A Longitudinal Study of COVID-19 Sequelae and Immunity

* 20-I-0117:
Surveillance of Individuals Following SARS-CoV-2 Exposure

* 20-I-0111:
COVID-19 associated Lymphopenia Pathogenesis Study in Blood

* 20-I-0084:
Sample Collection for Systems Evaluation of Patients with Unknown or Incompletely Characterized Immune Defects

* 20-I-0073:
A Multicenter, Adaptive, Randomized Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of COVID-19 in Hospitalized Adults

* 20-I-0037:
Matched Related and Unrelated Donor Stem Cell Transplantation for Severe Combined Immune Deficiency (SCID): Busulfan-based Conditioning with h-ATG, Radiation, and Sirolimus

* 20-I-0017:
VRC 612: A Phase 1, Dose Escalation, Open-Label Clinical Trial with Experimental Controlled Human Malaria Infections (CHMI) to Evaluate Safety and Protective Efficacy of an Anti-Malaria Human Monoclonal Antibody,VRC-MALMAB0100-00-AB (CIS43LS), in Healthy

* 20-I-0002:
Pilot Study of Mepolizumab in Episodic Angioedema with Eosinophilia

* 19-I-0140:
A Phase I Evaluation of the Safety of Belimumab in People with Idiopathaic CD4 Lymphopenia and Autoantibodies (Phoebe)

* 19-I-0133:
Paradoxical Tuberculosis Reactions in Patients without HIV Infection

* 19-I-0126:
Systems Analyses of the Immune Response to the Seasonal Influenza Vaccine

* 19-I-0093:
Collection of Human Biospecimens for Basic and Clinical Research into Alpha Globin Variants

* 19-I-0080:
Haploidentical Transplant for Patients with Chronic Granulomatous Disease (CGD) using Alemtuzumab, Busulfan and TBI with Post-Transplant Cyclophosphamide

* 19-I-0069:
Phase I Open-Label Study of Safety and Immunogenicity of AD4-HIV Envelope Vaccine Vectors in Healthy Volunteers

* 19-I-0053:
Prospective Study to Identify Food-Specific and Component IgE Threshold Levels that Predict Food Allergy in Patients with Elevated Total Serum IgE Levels and Atopic Dermatitis

* 19-I-0027:
A Phase 2 Randomized Double-Blinded Placebo-Controlled Study to Evaluate the Safety and Efficacy of Subcutaneous Sarilumab in Improving the Quality of Life in Subjects with Indolent Systemic Mastocytosis

* 19-I-0022:
A Prospective, Multicenter Study to Compare and Validate Endoscopic, Histologic, Molecular, and Patient-Reported Outcomes in Pediatric and Adult Patients with Eosinophilic Esophagitis (EoE), Gastritis (EG) and Colitis (EC)

* 18-I-0128:
Send-In Sample Collection to Achieve Genetic and Immunologic Characterization of Primary Immunodeficiencies

* 18-I-0105:
A Phase I, Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of a Human Monoclonal Antibody, VRC-HIVMAB091-00-AB (N6LS), Administered Intravenously or Subcutaneously with or without Recombinant Human Hyaluronidase PH20 (rHuPH20) to Hea

* 18-I-0101:
Sample Collection From Healthy Volunteers for Assay Optimization

* 18-I-0092:
A Phase 2, Open-Label Study to Assess the Immunogenicity of the 9-Valent Human Papillomavirus Recombinant Vaccine in Patients with Idiopathic CD4 T cell Lymphocytopenia

* 18-I-0075:
2-5 Intermittent Caloric Restriction for Weight Loss and insulin Resistance in HIV-Infected Adults with Features of the Metabolic Syndrome

* 18-I-0041:
The Mechanistic Biology of Primary Immunodeficiency Disorders

* 18-I-0030:
VRC 603: A Phase I Dose-Escalation Study of the Safety of AAV8-VRC07 (VRC-HIVAAV070-00-GT) Recombinant AAV Vector Expressing VRC07 HIV-1 Neutralizing Antibody in Antiretroviral -Treated, HIV-1 Infected Adults with Controlled Viremia.

* 18-I-0022:
Use of Ustekinumab (Anti-IL-12/23p40 Monoclonal Antibody) in Patients with Leukocyte Adhesion Deficiency Type 1 (LAD1) who have Inflammatory Pathology

* 17-I-0163:
Natural History of Intestinal Inflammation in Patients with Primary Immune Dysregulations

* 17-I-0122:
NIAID Centralized Sequencing Protocol

* 17-I-0101:
An Open-Label, Proof of Concept Study of Vorinostat for the Treatment of Moderate-to-Severe Crohn s Disease and Maintenance Therapy with Ustekinumab

* 17-I-0083:
Targeting Residual Activity By Precision, Biomarker-Guided Combination Therapies of Multiple Sclerosis (TRAP-MS)

* 17-I-0016:
Studies of the Natural History, Pathogenesis, and Outcome of Autoinflammatory Diseases (NOMID/CAPS, DIRA, CANDLE, SAVI, NLRC4-MAS, Still s-like Diseases, and Other Undifferentiated Autoinflammatory Diseases)

* 16-I-0165:
An Open-Label, Extension Study to Evaluate the Long Term Safety, Tolerability, Efficacy and Pharmacokinetics of Cdz173 in Patients with Apds/Pasli (Activated Phosphoinositide 3-Kinase Delta Syndrome/P110delta-Activating Mutation Causing Senescent T Cells

* 16-I-0126:
Genomic Response of Human Immune and Non-Immune Cells to Glucocorticoids

* 16-I-0078:
Microbial, Immune, and Metabolic Perturbations by Antibiotics (MIME study)

* 16-I-0065:
Screening for Alpha Globin Deletions

* 16-I-0053:
A Multicenter Study of the Immunogenicity of Recombinant Vesicular Stomatitis Vaccine for Ebola-Zaire (rVSVdeltaG-ZEBOV GP) for Pre-Exposure Prophylaxis in Individuals at Potential Occupational Risk for Ebola Virus Exposure (PREPARE)

* 16-I-0039:
Screening of Healthy Volunteers for Investigational Antimalarial Drugs, Malaria Vaccines, and Controlled Human Malaria Challenge

* 16-I-0032:
High Dose Peripheral Blood Stem Cell Transplantation with Post Transplant Cyclophosphamide for Patients with Chronic Granulomatous Disease

* 15-I-0162:
Natural History and Genetics of Food Allergy and Related Conditions

* 15-I-0154:
Long-Term Observation of Hemagglutinin and Neuraminidase Inhibition Antibody Titers After Influenza Challenge

* 15-I-0135:
An open-label, non-randomized, within-patient dose-finding study followed by a randomized, subject, investigator and sponsor-blinded placebo controlled study to assess the efficacy and safety of CDZ173 (Leniolisib) in patients with APDS/PASLI (Activated

* 15-I-0131:
Xenodiagnosis after Antibiotic Treatment for Lyme Disease - Phase II Study

* 15-I-0056:
Collection of Plasma from Subjects that Recovered From or Were Vaccinated To Emerging Infectious Diseases

* 14-I-0206:
Novel Genetic Disorders of the Immune System

* 14-I-0194:
Screening of Volunteers for Clinical Trials of Investigational or Licensed Vaccines or Antiviral Products

* 14-I-0146:
The Pathogenesis and Genetics of Disseminated or Refractory Coccidiodomycosis

* 14-I-0124:
PET Imaging and Lymph Node Assessment of IRIS in Persons With AIDS

* 14-I-0091:
Analysis of Patients Treated for Chronic Granulomatous Disease Since January 1, 1995

* 14-I-0089:
A Retrospective and Cross-Sectional Analysis of Patients Treated for Severe Combined Immunodeficiency (SCID) Since January 1, 1968

* 14-I-0072:
A Prospective Natural History Study of Diagnosis, Treatment and Outcomes of Children with SCID Disorders

* 14-I-0020:
Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models

* 14-I-0009:
Characterization and Management of Patients with HIV-1 Infection Who Experience Virologic Failure Despite Combination Antiretroviral Therapy

* 13-I-0157:
The Natural History of GATA2 Deficiency and Related Disorders

* 12-I-0157:
Clinical Outcomes of Persons with HIV Acquired Early in Life

* 12-I-0121:
Screening of Volunteers for Clinical Trials of Investigational and Licensed Vaccines, Antiviral Products, or Live Virus Challenge Studies

* 11-I-0187:
The Natural History and Pathogenesis of Human Fungal Infections

* 11-I-0183:
Screening for LID Clinical Studies Unit Healthy Volunteer Protocols

* 11-I-0164:
VRC 500: Screening of Volunteers for Clinical Trials of Investigational Products and Licensed Products Evaluated for Research Purposes

* 11-I-0109:
Viral Infections in Healthy and Immunocompromised Hosts

* 11-I-0007:
Lentiviral Gene Transfer for Treatment of Children Older Than 2 Years of Age with X-Linked Severe Combined Immunodeficiency

* 10-I-0216:
Studies of Disorders with Increased Susceptibility to Fungal Infections

* 10-I-0197:
Admission and Management of Occupational or Other Exposures to Biodefense/Bioterrorism Agents or to Epidemic/Emerging Infectious Diseases

* 10-I-0195:
Training Protocol on the Natural History of Tuberculosis

* 10-I-0148:
Natural History of Atopic Dermatitis and Other Genetic/Congenital Diseases Associated with Allergic Inflammation

* 10-I-0109:
VRC 900: Evaluation of Tissue-Specific Immune Responses in Adults 18 Years of Age and Older

* 10-I-0095:
Collection of Peripheral Blood Stem Cells Using G-CSF and Plerixafor in Healthy Volunteers

* 10-I-0014:
The Natural History of Severe Viral Infections and Characterization of Immune Defects

* 09-I-0232:
An International Observational Study to Characterize Adults Who Are Hospitalized with Complications of Influenza A-Pandemic H1N1 (H1N1v)

* 09-I-0200:
A Phase I Study of Mozobil (TM) in the Treatment of Patients with WHIMS

* 09-I-0184:
Studies in the Pathogenesis of Systemic Capillary Leak Syndrome

* 09-I-0133:
Establishing Fibroblast-derived Cell Lines from Skin/Tissue Biopsies of Patients with Immunodeficiency or Immunodysregulation Disorders

* 09-I-0126:
Pathogenesis and Genetic Basis of Physical Induced Urticarial Syndromes

* 09-I-0102:
Etiology, Pathogenesis, and Natural History of Idiopathic CD4+ Lymphocytopenia

* 09-I-0086:
Screening Protocol for Genetic Diseases of Allergic Inflammation

* 09-I-0049:
Normal Blood, Bone Marrow and Buccal Mucosa Protocol

* 09-I-0032:
Comprehensive Multimodal Analysis of Patients with Neuroimmunological Diseases of the CNS

* 09-I-0030:
Clinical and Immunologic Monitoring of Patients with Known or Suspected HIV Infection

* 09-I-0013:
Biomarkers of Inflammation, Coagulation, and Endothelial Function in HIV-Infected Adults

* 08-I-0221:
Analysis of HIV-1 Replication During Antiretroviral Therapy

* 08-I-0184:
Studies in the Pathogenesis of Anaphylaxis

* 07-I-0229:
Influenza in the Non-immunocompromised and Immunocompromised Host

* 07-I-0183:
The Collection of Research Samples and/or Data for Repository from Related or Unrelated Hematopoietic Stem Cell Transplantation Recipients for the National Marrow Donor Program

* 07-I-0033:
Screening Protocol for Detection and Characterization of Infections and Infection Susceptibility

* 06-I-0015:
Screening Protocol for Genetic Diseases of Lymphocyte Homeostasis and Programmed Cell Death

* 05-I-0213:
Screening and Baseline Assessment of Patients with Abnormalities of Immune Function

* 04-I-0286:
A Longitudinal Study of Familial Hypereosinophilia (FE): Natural History and Markers of Disease Progression

* 04-I-0266:
Collection of Blood, Body Fluid and Tissue Specimens from Healthy Donors for Use in In Vitro Research

* 03-I-0263:
VRC 200: A Multicenter Specimen Collection Protocol to Obtain Human Biological Samples for Research Studies

* 02-I-0286:
Efficacy of Tyrosine Kinase Inhibition in Reducing Eosinophilia in Patients with Myeloid and/or Steroid-Refractory Hypereosinophilic Syndrome

* 02-I-0277:
Regulation of the Proliferation and Survival of Normal and Neoplastic Human Mast Cells

* 02-I-0202:
Leukapheresis Procedures to Obtain Plasma and Lymphocytes for Research Studies on Antiretroviral Naive HIV-Infected Patients

* 02-I-0147:
Genetic Studies of Chronic Active Epstein-Barr Virus Infection

Next 74 Protocols

04/22/2021